166 related articles for article (PubMed ID: 24074031)
1. Vehicle selection for nonclinical oral safety studies.
Thackaberry EA
Expert Opin Drug Metab Toxicol; 2013 Dec; 9(12):1635-46. PubMed ID: 24074031
[TBL] [Abstract][Full Text] [Related]
2. High dose selection in general toxicity studies for drug development: A pharmaceutical industry perspective.
Buckley LA; Dorato MA
Regul Toxicol Pharmacol; 2009 Aug; 54(3):301-7. PubMed ID: 19477212
[TBL] [Abstract][Full Text] [Related]
3. Nonclinical vehicle use in studies by multiple routes in multiple species.
Gad SC; Cassidy CD; Aubert N; Spainhour B; Robbe H
Int J Toxicol; 2006; 25(6):499-521. PubMed ID: 17132609
[TBL] [Abstract][Full Text] [Related]
4. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies.
Pouton CW; Porter CJ
Adv Drug Deliv Rev; 2008 Mar; 60(6):625-37. PubMed ID: 18068260
[TBL] [Abstract][Full Text] [Related]
5. Role of excipients in successful development of self-emulsifying/microemulsifying drug delivery system (SEDDS/SMEDDS).
Rahman MA; Hussain A; Hussain MS; Mirza MA; Iqbal Z
Drug Dev Ind Pharm; 2013 Jan; 39(1):1-19. PubMed ID: 22372916
[TBL] [Abstract][Full Text] [Related]
6. Drug delivery strategies for poorly water-soluble drugs: the industrial perspective.
van Hoogevest P; Liu X; Fahr A
Expert Opin Drug Deliv; 2011 Nov; 8(11):1481-500. PubMed ID: 21895540
[TBL] [Abstract][Full Text] [Related]
7. A review of the nonclinical safety of Transcutol®, a highly purified form of diethylene glycol monoethyl ether (DEGEE) used as a pharmaceutical excipient.
Sullivan DW; Gad SC; Julien M
Food Chem Toxicol; 2014 Oct; 72():40-50. PubMed ID: 25016034
[TBL] [Abstract][Full Text] [Related]
8. Self-emulsifying drug delivery systems: an approach to enhance oral bioavailability.
Kohli K; Chopra S; Dhar D; Arora S; Khar RK
Drug Discov Today; 2010 Nov; 15(21-22):958-65. PubMed ID: 20727418
[TBL] [Abstract][Full Text] [Related]
9. Tolerable Levels of Nonclinical Vehicles and Formulations Used in Studies by Multiple Routes in Multiple Species With Notes on Methods to Improve Utility.
Gad SC; Spainhour CB; Shoemake C; Pallman DR; Stricker-Krongrad A; Downing PA; Seals RE; Eagle LA; Polhamus K; Daly J
Int J Toxicol; 2016; 35(2):95-178. PubMed ID: 26755718
[TBL] [Abstract][Full Text] [Related]
10. Nonclinical aspects of biopharmaceutical development: discussion of case studies at a PhRMA-FDA workshop.
Buckley LA; Benson K; Davis-Bruno K; Dempster M; Finch GL; Harlow P; Haggerty HG; Hart T; Kinter L; Leighton JK; McNulty J; Roskos L; Saber H; Stauber A; Tabrizi M
Int J Toxicol; 2008; 27(4):303-12. PubMed ID: 18821393
[TBL] [Abstract][Full Text] [Related]
11. Preparation and evaluation of ibuprofen-loaded microemulsion for improvement of oral bioavailability.
Hu L; Yang J; Liu W; Li L
Drug Deliv; 2011 Jan; 18(1):90-5. PubMed ID: 20942639
[TBL] [Abstract][Full Text] [Related]
12. Preclinical formulations: insight, strategies, and practical considerations.
Shah SM; Jain AS; Kaushik R; Nagarsenker MS; Nerurkar MJ
AAPS PharmSciTech; 2014 Oct; 15(5):1307-23. PubMed ID: 24920522
[TBL] [Abstract][Full Text] [Related]
13. Developing early formulations: practice and perspective.
Li P; Zhao L
Int J Pharm; 2007 Aug; 341(1-2):1-19. PubMed ID: 17658228
[TBL] [Abstract][Full Text] [Related]
14. High drug loading self-microemulsifying/micelle formulation: design by high-throughput formulation screening system and in vivo evaluation.
Sakai K; Obata K; Yoshikawa M; Takano R; Shibata M; Maeda H; Mizutani A; Terada K
Drug Dev Ind Pharm; 2012 Oct; 38(10):1254-61. PubMed ID: 22339057
[TBL] [Abstract][Full Text] [Related]
15. Recent advances and novel strategies in pre-clinical formulation development: an overview.
Shah AK; Agnihotri SA
J Control Release; 2011 Dec; 156(3):281-96. PubMed ID: 21763367
[TBL] [Abstract][Full Text] [Related]
16. Toxicologic Pathology Forum: Current Status on the Use of Animal Models of Human Disease in the Pharmaceutical Industry in Japan in Nonclinical Safety Assessment-Opinion Paper.
Tomohiro M; Okabe T; Kimura Y; Kinoshita K; Maeda M; Mitobe Y; Motoyama K; Yonezawa R; Sasaki S; Fujiwara M; Watanabe K
Toxicol Pathol; 2019 Feb; 47(2):108-120. PubMed ID: 30636562
[TBL] [Abstract][Full Text] [Related]
17. Pharmaceutical excipient development: the need for preclinical guidance.
Baldrick P
Regul Toxicol Pharmacol; 2000 Oct; 32(2):210-8. PubMed ID: 11067777
[TBL] [Abstract][Full Text] [Related]
18. Liquid spray formulations of xibornol by using self-microemulsifying drug delivery systems.
Cirri M; Mura P; Mora PC
Int J Pharm; 2007 Aug; 340(1-2):84-91. PubMed ID: 17531411
[TBL] [Abstract][Full Text] [Related]
19. Challenges and opportunities in the encapsulation of liquid and semi-solid formulations into capsules for oral administration.
Cole ET; Cadé D; Benameur H
Adv Drug Deliv Rev; 2008 Mar; 60(6):747-56. PubMed ID: 18096270
[TBL] [Abstract][Full Text] [Related]
20. A strategy for preclinical formulation development using GastroPlus as pharmacokinetic simulation tool and a statistical screening design applied to a dog study.
Kuentz M; Nick S; Parrott N; Röthlisberger D
Eur J Pharm Sci; 2006 Jan; 27(1):91-9. PubMed ID: 16219449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
